NEWS

WHAT WE DO

Cancer Diagnosis: The importance of early diagnosis

Cancer is currently the leading cause of death in Japan. With advances in diagnosis and treatment, early detection and early treatment are becoming possible for certain types of cancer, and if detected early, there is a high probability of recovery and successful treatment. Exosomes secreted from pathological tissues such as cancer cells contain disease-related molecules. Theoria Science has developed an original technology that detects exosomes in the blood, enabling the early detection of cancer.

TECHNOLOGY

What are exosomes?

Exosomes are granules approximately 30 to 200 nm in diameter encapsulated in a lipid bilayer that are secreted by the cells that make up the living body, from unicellular organisms to higher organisms. They are produced and secreted by virtually all of the cells in the body, and in humans, they are found in various body fluids such as breast milk, saliva, and tears in addition to the blood and urine. Analyzing and researching the molecules contained on the surface and interior of exosomes is expected to lead to the elucidation of new physiological functions and relationships with diseases, and they are rapidly drawing attention. According to the publisher Elsevier, in 2017, research on exosomes / extracellular vesicles surpassed research on genome editing and CAR-T therapy, and was the area that saw the greatest increase in the number of papers published globally.

About us

Message from Takahiro Ochiya, CSO

The purpose of the Research Department of Theoria Science is to establish new methods of diagnosis and treatment for various diseases including cancer. We have specialized technologies in the areas of nucleic acid medicine, biological imaging, stem cells, regenerative medicine, cell engineering, and molecular oncology, and based on our accumulated experience in these areas, we are constantly taking on the challenge of exploring new areas.

Management

Takayuki Mizutani

Takayuki MizutaniRepresentative Director

1997
Graduated from the Department of Chemistry and Biochemistry, Ohio State University, USA
2000
M.S. in Biochemistry, California State University Long Beach, USA
2000
Joined B-Bridge International, Inc. (San Jose, CA)
2003
Founded AVOCEL Inc. (Mt, View, CA)
2010
Founded IZM Corporation, Representative Director
2012
Completed doctoral program, Department of Molecular Pathology, Graduate School of Medicine, Tokyo Medical University (Ph.D.)
2012
Director, Bonac Corporation
2014
Representative Director, Theoria Science K.K.
Takahiro Ochiya

Takahiro OchiyaDirector, CSO

1988
Completed doctoral program, Graduate School of Medicine, Osaka University (Ph.D.)
1988
Instructor Assistant, Osaka University Institute for Molecular & Cellular Biology
1991
Postdoctoral Fellow, La Jolla Cancer Research Foundation (now the Sanford Burnham Prebys Medical Discovery Institute)
1993
Senior researcher, National Cancer Center Research Institute, later Head, Department of Molecular Oncology, and Head, Department of Cancer Metastasis Research
2010
Chief, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute
2012
Director, Theoria Science K.K.
2018
Professor, Institute of Medical Science, Tokyo Medical University
Akihiko Asami

Akihiko AsamiExternal Director

1985
Graduated from the Faculty of Economics, School of Political Science and Economics, Waseda University
1985
Joined The Fuji Bank, Limited
1996
Completed master’s program, Sloan School of Management, Massachusetts Institute of Technology, U.S.A.
1996
Joined Goldman Sachs Japan Investment Banking Division
2004
Managing Director, Goldman Sachs Japan Investment Banking Division
2009
Head, Technology, Media, and Telecom Sector Group and Head, Healthcare Group, Investment Banking Division, Deutsche Securities Inc.
2012
Head of Corporate Finance, Investment Banking Japan, Barclays Capital Japan Limited
2014
Division Head, Investment Banking Japan, Barclays Capital Japan Limited
2016
Vice President, Barclays Capital Japan Limited
2019
Director and CFO, Theoria Science K.K.
Yutaro Kasai

Yutaro KasaiPart-Time Auditor

2005
Graduated from the Graduate School of Agricultural and Life Sciences, The University of Tokyo
2005
Joined Goldman Sachs Japan Investment Banking Division
2006
Joined Bain Capital, LP
2009
Entered the Booth School of Business, University of Chicago
2011
Joined Unison Capital, Inc.
2015
Established Angel Bridge K.K., Representative Director
2019
Part-Time Auditor, Theoria Science K.K.

Company Overview

Mission

  • Prevention

    Preventive drug development

  • Early detection

    Early diagnostic drug development

  • Early treatment

    Early therapeutic drug development

  • Making current impossibilities future possibilities

    Taking on the challenge of development of therapeutic and diagnostic drugs for intractable diseases